Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanadelumab in Chinese Subjects With Hereditary Angioedema
NCT05460325Phase 3Completed
- Sponsor
- Takeda
- Start
- Jun 2022
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of lanadelumab in hereditary angioedema (HAE), sponsored by Takeda. Started Jun 2022; status: completed.
02
Drugs
lanadelumab
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT05460325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05460325.